Analystreport

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target raised by analysts at Robert W. Baird from $160.00 to $209.00. They now have an "outperform" rating on the stock.

Jazz Pharmaceuticals plc - Ordinary Shares  (JAZZ) 
Last jazz pharmaceuticals plc - ordinary shares earnings: 2/25 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: jazzpharma.com